Retatrutide

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

Retatrutide — GLP-1R / GIPR / GcgR Triple Agonist

Retatrutide is a synthetic peptide that simultaneously activates three distinct metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple-receptor profile makes it one of the most mechanistically complex compounds available for metabolic research, and a subject of significant scientific interest in the study of energy balance, adipose tissue dynamics, and glucose homeostasis.

Why Triple Agonism Matters

Most peptides in this category are single or dual agonists. Retatrutide’s third receptor — the glucagon receptor (GcgR) — is what distinguishes it from the rest of the field.

GLP-1 and GIP work primarily through appetite and insulin pathways. Glucagon receptor agonism adds a separate mechanism — it drives the body to burn stored fat directly and raises basal energy expenditure. The combination means researchers can study both sides of the energy equation (intake and expenditure) in a single compound.

Research Applications

Retatrutide is used in studies examining:

• Body composition changes under sustained caloric restriction
• Comparative efficacy of multi-agonist vs. mono/dual-agonist protocols
• Glucose and insulin dynamics in metabolic models
• Hepatic lipid accumulation and fatty liver pathways
• Dose-response relationships in incremental titration protocols

Specifications

Reconstitution

Retatrutide arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example: 10mg vial + 2mL BAC water = 5mg/mL solution

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

Due to its potency at all three receptor sites, incremental titration is standard practice in research protocols to characterize the dose-response curve and allow for observation of receptor adaptation at each stage.

Typical titration framework:

• Starting dose: 0.5–1mg per administration
• Escalation: Increase by 0.5–1mg every 1–2 weeks as tolerated
• Frequency: Weekly or biweekly
• Study duration: 8–12 weeks for body composition endpoints

Commonly observed effects in research models:

• GI-related (receptor-mediated, typically transient): Nausea, early satiety, reduced appetite, mild digestive discomfort — most pronounced during dose escalation and generally self-limiting
• Metabolic: Reduced caloric intake, fluid balance shifts, electrolyte considerations at higher doses
• Other: Injection site irritation, headache, lightheadedness at escalation intervals

Research Stacks

Retatrutide is commonly paired in research settings with:

• CJC-1295 No DAC / Ipamorelin — CJC-1295 No DAC and Ipamorelin stimulate pulsatile GH secretion via GHRH and ghrelin receptor pathways; combining with Retatrutide allows researchers to examine GLP-1/GIP/glucagon triple agonism alongside GH axis activity in models of metabolic regulation.
• MOTS-c — MOTS-c is a mitochondrial-derived peptide that activates AMPK and enhances insulin sensitivity at the cellular level. Pairing with Retatrutide, which engages incretin and glucagon receptor pathways, provides a model for studying complementary central and peripheral metabolic mechanisms.
• Semaglutide — As a mono-selective GLP-1 receptor agonist, Semaglutide is used alongside Retatrutide in comparative studies to isolate incretin-specific effects from the additive contributions of GIP and glucagon receptor co-agonism.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.